Such a restoration of UTX activity by efficient therapies is consistent with the role of UTX as a well-known tumour suppressor in certain cancer types [86]; however, it should be acknowledged that UTX inactivation has non-uniform effects and demands further investigation of specific outcomes in different human malignancies [87, 88]. The gene discussed is KDM6A; the disease is cancer.